Driving Forward Molecular Glues – Pre-Clinical & Clinical Data with Lead Molecular Glue Degraders
Time: 4:00 pm
day: Conference Day Two
Details:
- Advancing small molecule degraders D7 for TNBC and 433Beta for prostate cancers – tumor regression in animal models
- Uncovering the mechanism of molecular glue induced degradation of Androgen Receptor and MNK1/2
- Showcasing the results from a Phase II human clinical trial in PDAC with a molecular glue
New Company
